Vijaya Diagnostic Centre Limited - Asset Resilience Ratio

Latest as of September 2025: 16.44%

Vijaya Diagnostic Centre Limited (VIJAYA) has an Asset Resilience Ratio of 16.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Vijaya Diagnostic Centre Limited balance sheet assets for the complete picture of this company's asset base.

Liquid Assets

Rs2.29 Billion
≈ $24.73 Million USD Cash + Short-term Investments

Total Assets

Rs13.91 Billion
≈ $150.40 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Vijaya Diagnostic Centre Limited's Asset Resilience Ratio has changed over time. See how leveraged is Vijaya Diagnostic Centre Limited's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Vijaya Diagnostic Centre Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vijaya Diagnostic Centre Limited (VIJAYA) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs2.29 Billion 16.44%
Total Liquid Assets Rs2.29 Billion 16.44%

Asset Resilience Insights

  • Good Liquidity Position: Vijaya Diagnostic Centre Limited maintains a healthy 16.44% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Vijaya Diagnostic Centre Limited Industry Peers by Asset Resilience Ratio

Compare Vijaya Diagnostic Centre Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
SMO ClinPlus Co. Ltd.
SHE:301257
Diagnostics & Research 15.78%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Check-Cap Ltd.
NASDAQ:MBAI
Diagnostics & Research 2.90%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%

Annual Asset Resilience Ratio for Vijaya Diagnostic Centre Limited (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Vijaya Diagnostic Centre Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 14.49% Rs1.85 Billion
≈ $19.96 Million
Rs12.74 Billion
≈ $137.74 Million
+3.39pp
2024-03-31 11.10% Rs1.09 Billion
≈ $11.80 Million
Rs9.83 Billion
≈ $106.28 Million
-15.99pp
2023-03-31 27.10% Rs2.31 Billion
≈ $25.01 Million
Rs8.53 Billion
≈ $92.29 Million
-2.91pp
2022-03-31 30.01% Rs2.14 Billion
≈ $23.15 Million
Rs7.13 Billion
≈ $77.16 Million
-9.35pp
2021-03-31 39.36% Rs2.13 Billion
≈ $23.02 Million
Rs5.41 Billion
≈ $58.50 Million
+15.49pp
2020-03-31 23.86% Rs1.15 Billion
≈ $12.45 Million
Rs4.82 Billion
≈ $52.15 Million
-3.16pp
2019-03-31 27.03% Rs1.10 Billion
≈ $11.88 Million
Rs4.06 Billion
≈ $43.95 Million
--
pp = percentage points

About Vijaya Diagnostic Centre Limited

NSE:VIJAYA India Diagnostics & Research
Market Cap
$1.40 Billion
Rs129.79 Billion INR
Market Cap Rank
#7707 Global
#362 in India
Share Price
Rs1261.40
Change (1 day)
+0.14%
52-Week Range
Rs861.40 - Rs1342.60
All Time High
Rs1342.60
About

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T ser… Read more